Rapid Reactions: Eli Lilly Acquisition Highlights Momentum in Psychedelics for Mental Health
Key Takeaways for Clinical Practice
- Eli Lilly will acquire AtaiBeckley for up to $3.8 billion, expanding its presence in the emerging field of psychedelic-based mental health treatment.
- The acquisition adds BPL-003 (mebufotenin benzoate), a psychedelic-based nasal spray in late-stage development for treatment-resistant depression (TRD), to Lilly's neuroscience portfolio.
- The transaction reflects increasing pharmaceutical investment in psychedelic therapies for mental health disorders.
On Thursday, July 16, Eli Lilly and Company announced plans to acquire AtaiBeckley Inc in a deal valued at up to $3.8 billion, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
The acquisition gives Lilly access to BPL-003 (mebufotenin benzoate), an intranasally-administered synthetic form of 5-MeO-DMT, currently in late-stage development for treatment-resistant depression (TRD).
In a phase 2b trial, BPL-003, which received US Food and Drug Administration (FDA) Breakthrough Therapy Designation, demonstrated rapid and durable reductions in depressive symptoms following an in-clinic visit, with several months of beneficial effect. Initial results from the late-stage clinical trials are expected in early 2029.
"Millions of people are still searching for relief and desperately need a therapy that works," said Carole Ho, executive vice president and president, Lilly Neuroscience, in a press release. "Advancing AtaiBeckley's investigational therapies gives us a real chance to change that."
The deal comes as pharmaceutical companies increase investment in psychedelic therapeutics amid growing interest in the field. A series of federal actions in April supporting the acceleration of psychedelic therapy review and expanding research funding further pushed these emerging treatments into focus.
Rakesh Jain, MD, MPH, Responds
“This is big and important news,” Rakesh Jain, MD, MPH, Psych Congress Co-Chair told Psych Congress Network, “…because a company like Lilly has huge research prowess, and for them to acquire these medications really tells us that psychedelic sciences have come into prominence.”
“AtaiBeckley has a couple of medications in development that hold great promise as very rapid-acting antidepressants [and a] durability of effect that is in some ways astonishing,” Jain added.
“This is the beginning of a new era in psychiatry,” he emphasized.
The companies plan to close the transaction in the third quarter, pending stockholder approval and satisfaction of other customary closing conditions.
Watch the video above for Dr Jain’s full response to this breaking news.
Read the Transcript:
Rakesh Jain, MD, MPH: Hello friends. Just today we found out some important news that's relevant to the world of psychiatry at large, which is that Lilly pharmaceuticals is going to acquire AtaiBeckley, which is a really important research company developing medications that are psychedelic in nature for the treatment of serious mental disorders, such as major depression. This is big news.
This is big and important news for our patients, for our clinicians and the world at large, because a company like Lilly pharmaceuticals has huge research prowess, and for them to acquire these medications really does tell us that psychedelic sciences have come into prominence and that they hold great future.
AtaiBeckley has a couple of medications in development that hold great promise as very rapid-acting antidepressants—not only rapid, but have durability of effect that is in some ways astonishing.
At Psych Congress, we really aim to keep the community at large abreast of new and important developments, and this certainly qualifies as one. We at Psych Congress plan to cover this topic and other topics relevant to the world of psychiatry and psychedelic sciences quite thoroughly.
Perhaps at Psych Congress this year, I will get to see you so that we can continue this discussion.
But this is big news and I wanted to share this with you. We wanted to share this with you from the Psych Congress family as soon as we possibly could.
Stay tuned and let's continue this important conversation. But this is the beginning of a new era in psychiatry.
References
Rakesh Jain, MD, MPH, attended medical school at the University of Calcutta in India. He then attended graduate school at the University of Texas School of Public Health in Houston, where he was awarded a “National Institute/Center for Disease Control Competitive Traineeship”. His research thesis focused on impact of substance abuse. He graduated from the School of Public Health in 1987 with a Masters of Public Health (MPH) degree.
Dr Jain served a 3-year residency in Psychiatry at the Department of Psychiatry and Behavioral Sciences at the University of Texas Medical School at Houston. He followed that by obtaining further specialty training, by undergoing a 2-year fellowship in Child and Adolescent Psychiatry. In addition, Dr Jain completed a postdoctoral fellowship in Research Psychiatry at the University of Texas Mental Sciences Institute, in Houston. He was awarded the “National Research Service Award” for the support of this postdoctoral fellowship.
© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed above are those of the author(s) and do not necessarily reflect the views, policy, or position of the Psych Congress Network or HMP Global, their employees, and affiliates.
